New directions for ZD1839 in the treatment of solid tumors

Joan H. Schiller

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalence and Impact on many different solid tumor types, as well as its link to diverse stages of disease. ZD1839, (Iressa; AstraZeneca Pharmaceuficals LP, Wilmington, DE) an oral epidermal growth factor receptor-tyrosine Kinase inhibitor, is also being explored for its potential in the treatment of other common solid tumors, including breast cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials include studies of ZD1839 as monotherapy and in combination with varlous chemotherapy, radiation, and hormone therapy regimens. ZD1839 is also being studied in conjunction with other targeted therapies, such as trastuzumab. In addition to advanced and refractory disease, ZD1839 may also be applicable for use in earlier stage cancers. Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalSeminars in Oncology
Volume30
Issue number1 SUPPL. 1
DOIs
StatePublished - Feb 2003

Fingerprint

Neoplasms
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Hormones
Chemoprevention
Non-Small Cell Lung Carcinoma
Direction compound
gefitinib
Colorectal Neoplasms
Prostatic Neoplasms
Radiotherapy
Clinical Trials
Breast Neoplasms
Drug Therapy
Growth
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

New directions for ZD1839 in the treatment of solid tumors. / Schiller, Joan H.

In: Seminars in Oncology, Vol. 30, No. 1 SUPPL. 1, 02.2003, p. 49-55.

Research output: Contribution to journalArticle

Schiller, Joan H. / New directions for ZD1839 in the treatment of solid tumors. In: Seminars in Oncology. 2003 ; Vol. 30, No. 1 SUPPL. 1. pp. 49-55.
@article{03c8e0aef33245b3aa3df02bb5778982,
title = "New directions for ZD1839 in the treatment of solid tumors",
abstract = "Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalence and Impact on many different solid tumor types, as well as its link to diverse stages of disease. ZD1839, (Iressa; AstraZeneca Pharmaceuficals LP, Wilmington, DE) an oral epidermal growth factor receptor-tyrosine Kinase inhibitor, is also being explored for its potential in the treatment of other common solid tumors, including breast cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials include studies of ZD1839 as monotherapy and in combination with varlous chemotherapy, radiation, and hormone therapy regimens. ZD1839 is also being studied in conjunction with other targeted therapies, such as trastuzumab. In addition to advanced and refractory disease, ZD1839 may also be applicable for use in earlier stage cancers. Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer.",
author = "Schiller, {Joan H.}",
year = "2003",
month = "2",
doi = "10.1053/sonc.2003.50032",
language = "English (US)",
volume = "30",
pages = "49--55",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - New directions for ZD1839 in the treatment of solid tumors

AU - Schiller, Joan H.

PY - 2003/2

Y1 - 2003/2

N2 - Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalence and Impact on many different solid tumor types, as well as its link to diverse stages of disease. ZD1839, (Iressa; AstraZeneca Pharmaceuficals LP, Wilmington, DE) an oral epidermal growth factor receptor-tyrosine Kinase inhibitor, is also being explored for its potential in the treatment of other common solid tumors, including breast cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials include studies of ZD1839 as monotherapy and in combination with varlous chemotherapy, radiation, and hormone therapy regimens. ZD1839 is also being studied in conjunction with other targeted therapies, such as trastuzumab. In addition to advanced and refractory disease, ZD1839 may also be applicable for use in earlier stage cancers. Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer.

AB - Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalence and Impact on many different solid tumor types, as well as its link to diverse stages of disease. ZD1839, (Iressa; AstraZeneca Pharmaceuficals LP, Wilmington, DE) an oral epidermal growth factor receptor-tyrosine Kinase inhibitor, is also being explored for its potential in the treatment of other common solid tumors, including breast cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials include studies of ZD1839 as monotherapy and in combination with varlous chemotherapy, radiation, and hormone therapy regimens. ZD1839 is also being studied in conjunction with other targeted therapies, such as trastuzumab. In addition to advanced and refractory disease, ZD1839 may also be applicable for use in earlier stage cancers. Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037298141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037298141&partnerID=8YFLogxK

U2 - 10.1053/sonc.2003.50032

DO - 10.1053/sonc.2003.50032

M3 - Article

C2 - 12644984

AN - SCOPUS:0037298141

VL - 30

SP - 49

EP - 55

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -